David James Lennon - 01 Apr 2026 Form 4 Insider Report for Whitehawk Therapeutics, Inc. (WHWK)

Source evidence Original filing metadata and source links for verification. 5 source fields
SEC form
4
Accepted by SEC
03 Apr 2026, 18:17:15 UTC
Prior SEC filing
10 Mar 2026
Next SEC filing
08 Apr 2026
Source filing
View source filing
Reporting owner 1 detail
Reporting owner signature
/s/ Stephen Rodin, as Attorney-in-Fact

Key filing fact

David James Lennon filed Form 4 for Whitehawk Therapeutics, Inc. (WHWK) on 03 Apr 2026.

Key facts

  • This page summarizes David James Lennon's Form 4 filing for Whitehawk Therapeutics, Inc. (WHWK).
  • 4 reported transactions and 2 derivative rows are listed below.
  • Accepted by SEC: 03 Apr 2026, 18:17.

Change

  • Previous filing in this sequence was filed on 10 Mar 2026.
  • Current net transaction value: -$93,466.

Research use

  • This tells you what this filing adds before you inspect full transaction and derivative tables.
  • You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0001995275 Primary reporting owner

Lennon David James

Relationship
CHIEF EXECUTIVE OFFICER, Director
Address
C/O WHITEHAWK THERAPEUTICS, INC., 2 HEADQUARTERS PLAZA, EAST BUILDING, 11T, MORRISTOWN
Signature
/s/ Stephen Rodin, as Attorney-in-Fact
Signature date
03 Apr 2026

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

WHWK transaction

Common Stock

Options Exercise

Transaction value
Shares
+775,828
Change %
+1740%
Price
Shares after
820,407
Date
01 Apr 2026
Ownership
Direct
Footnotes
F1
WHWK transaction

Common Stock

Sale

Transaction value
$93,466
Shares
-26,858
Change %
-3.3%
Price
$3.48
Shares after
793,549
Date
02 Apr 2026
Ownership
Direct
Footnotes
F2

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

WHWK transaction Derivative

Restricted Stock Units

Options Exercise

Transaction value
Shares
-775,828
Change %
-100%
Price
$0.000000*
Shares after
0
Date
01 Apr 2026
Ownership
Direct
Underlying class
Common Stock
Underlying amount
775,828
Exercise price
Footnotes
F1, F3
WHWK transaction Derivative

Stock Option (right to buy)

Award

Transaction value
Shares
+831,148
Change %
Price
$0.000000*
Shares after
831,148
Date
01 Apr 2026
Ownership
Direct
Underlying class
Common Stock
Underlying amount
831,148
Exercise price
$3.54
Footnotes
F4
* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 4 footnotes

Footnote F1

Each restricted stock unit ("RSU") represents a contingent right to receive one share of Whitehawk Therapeutics, Inc. Common Stock.

Footnote F2

Represents a broker-assisted sale to satisfy the Reporting Person's tax withholding obligations in connection with the vesting of restricted stock units.

Footnote F3

Subject to the Reporting Person continuing to be a Service Provider (as defined in the Issuer's 2021 Equity Incentive Plan) through each applicable date, one hundred percent (100%) of the shares subject to the award shall vest on the one-year anniversary of the Vesting Commencement Date. "Vesting Commencement Date" shall mean April 1, 2025.

Footnote F4

Subject to the Reporting Person continuing to be a Service Provider (as defined in the Issuer's 2021 Equity Incentive Plan) through each applicable date, twenty five percent (25%) of the shares subject to the option shall vest on the one-year anniversary of the Vesting Commencement Date and 1/48th of the total shares subject to the Option shall vest every month thereafter such that all shares subject to the option shall be fully vested on the four-year anniversary of the Vesting Commencement Date. "Vesting Commencement Date" shall mean April 1, 2026.

We use cookies and similar technologies to provide certain features, enhance the user experience and, if you allow them, measure engagement and deliver advertising. Analytics and marketing storage stay off until you grant consent. By clicking on "Agree and continue", you declare your consent to the use of the selected optional cookies. Manage preferences to update or revoke optional consent for future visits. For more information, see our Privacy Policy .